Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Lung Diseases, Interstitial » Granulomatosis with Polyangiitis
Diseases [C] » Cardiovascular Diseases [C14] » Vascular Diseases » Vasculitis » Systemic Vasculitis » Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis » Granulomatosis with Polyangiitis
Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis » Granulomatosis with Polyangiitis
Description
A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN. MeSH
Hierarchy View
Approved Indicated Drugs (2)
Phase 3 Indicated Drugs (3)
Phase 2 Indicated Drugs (7)
Phase 1 Indicated Drugs (1)
Other Experimental Indicated Drugs (5)
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (30)
National Center for Advancing Translational Science (NCATS)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Organization Involved with Phase 2 Indications (11)
Organization Involved with Other Experimental Indications (3)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
